Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 139.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,919 shares of the company’s stock after purchasing an additional 129,944 shares during the period. Barclays PLC owned approximately 0.26% of Verve Therapeutics worth $1,079,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Creative Planning acquired a new position in Verve Therapeutics during the 3rd quarter worth about $50,000. PFG Investments LLC purchased a new position in Verve Therapeutics in the 3rd quarter valued at approximately $53,000. Erste Asset Management GmbH purchased a new position in Verve Therapeutics in the 3rd quarter valued at approximately $56,000. Daiwa Securities Group Inc. grew its stake in shares of Verve Therapeutics by 89.8% in the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after acquiring an additional 5,723 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Verve Therapeutics in the third quarter valued at $74,000. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

Verve Therapeutics Price Performance

Shares of NASDAQ VERV opened at $5.25 on Wednesday. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34. The company has a market capitalization of $444.49 million, a price-to-earnings ratio of -2.13 and a beta of 1.68. The business has a 50-day moving average of $5.83 and a two-hundred day moving average of $5.74.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. The firm had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm’s quarterly revenue was up 120.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.72) earnings per share. As a group, equities research analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on VERV. Royal Bank of Canada lowered their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Canaccord Genuity Group upped their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright decreased their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.